Akèy › Kansè tete negatif triple › Kalifòni › Mountain View
Etid klinik pou Kansè tete negatif triple nan Mountain View, CA
8 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Mountain View (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Stanford University, Palo Alto · 5 mi lwen
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Ap rekriteFaz 3
- El Camino Hospital Cancer Center ( Site 0096), Mountain View
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
Ap rekriteFaz 2
- Stanford University, Stanford · 5 mi lwen
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Local Institution - 0358, Stanford · 5 mi lwen
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Ap rekriteFaz 1
- Stanford University Medical Center, Palo Alto · 5 mi lwen
A Study of LY4175408 in Participants With Advanced Cancer
Ap rekriteFaz 1
- Stanford Medicine Cancer Center, Stanford · 5 mi lwen
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Ap rekriteFaz 1/2
- Stanford Women's Cancer Center, Palo Alto · 5 mi lwen
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Ap rekriteFaz 1
- Stanford University, Stanford · 5 mi lwen
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Atlanta, GA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
Lòt etid nan Mountain View
- Kansè (tout kalite)40 etid
- Kansè nan tete26 etid
- Kansè Metastatik25 etid
- Kansè Poumon ki pa ti selil21 etid
- Leksemi mieloïd egi19 etid
- Kansè ovè19 etid
- Twoub Spektòm Otis17 etid
- Kansè poumon17 etid
- Kansè pwostat15 etid
- Ensifizyans kadyak15 etid
- Otis13 etid
- Leksemi limfoblastik egi13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.